Clinical trials: Sirolimus, completed
Non-Hodgkins Lymphoma
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for…
- Trial name
- NCT01281917
- Testing
- Velcade, Temsirolimus
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Wisconsin, Madison
Advanced Breast Cancer
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
This study aimed at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on…
- Trial name
- BOLERO-5 (NCT03312738)
- Testing
- Everolimus, Exemestane
- Where
- 15 sites in China
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
de Novo Kidney Transplant Recipients, Renal Transplantation
Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.
This study will compare the following immunosuppressive regimens in recipients of kidney transplantation: A) everolimus, cyclosporine and steroids given once-a-day; B) everolimus and cyclosporine given twice a day with steroid…
- Trial name
- EVIDENCE (NCT01023815)
- Testing
- everolimus, cyclosporine, Prednison (continuous steroids)
- Where
- 28 sites in Italy
- Volunteers
- 330 people
- Sponsor
- Novartis
Advanced Solid Tumors
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
This study is for people with advanced cancer for which no curative treatment exists. The purpose of this study is to test the safety and effectiveness of the combination of the drugs Temsirolimus and Capecitabine and see what…
- Trial name
- NCT01050985
- Testing
- Temsirolimus and capecitabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Georgetown University
Tuberous Sclerosis Complex
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
- Trial name
- NCT05495425
- Testing
- NPC-12Y gel
- Where
- 5 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Nobelpharma
Kidney Transplantation, Immunity
Protective Immunity Project 01
Patients who undergo kidney transplant must take medications to prevent organ rejection. There are standard immunosuppressant medications such as prednisone, tacrolimus (Prograf), mycophenolate mofetil(Cellcept) or sirolimus…
- Conditions
- Kidney Transplantation, Immunity, Immunosuppression
- Trial name
- PIP-01 (NCT00788021)
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Emory University
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
This is a phase I single center dose escalation study with an extension at the best available dose to determine the tolerability of inducible regulatory T cells (iTregs) when given to adult patients undergoing non-myeloablative…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin Lymphoma
- Trial name
- NCT01634217
- Testing
- iTreg
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Sclerosis, Relapsing-Remitting
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.
- Trial name
- NCT00228397
- Testing
- CCI-779
- Volunteers
- 221 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Carcinoma, Renal Cell
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The purpose of this study is to see whether the combination for RAD001 and Nexavar® works better when given together than they do alone.
- Trial name
- NCT00448149
- Testing
- RAD001, Sorafenib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- The Methodist Hospital Research Institute
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Liver Transplantation
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
The purpose of this trial was to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.
- Trial name
- NCT01888432
- Testing
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Where
- 42 sites in United States, Canada and 11 more
- Volunteers
- 285 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL)
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide…
- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma
- Trial name
- NCT02793544
- Testing
- Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Carcinoma, Renal Cell
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.
- Trial name
- NCT02454478
- Testing
- Lenvatinib, Everolimus
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Eisai Co., Ltd.
Renal Cell Carcinoma
Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma
Temsirolimus is a drug that is being studied to possibly treat kidney cancer. It works by starving the cancer of nutrients, by cutting off the blood supply, which is hoping to shrink the cancer.
- Trial name
- NCT01404104
- Testing
- Temsirolimus (pre surgery)
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Non-Hodgkin's Lymphoma
A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This study assesses the tolerability, safety, efficacy and pharmacokinetics of everolimus in Japanese patients. Everolimus is administered orally everyday to adult patients with relapsed or refractory non-Hodgkin's lymphoma who…
- Trial name
- NCT00622258
- Testing
- Everolmus
- Where
- 8 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplantation
REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C…
- Trial name
- REFLECT (NCT02115113)
- Testing
- Everolimus, Tacrolimus
- Where
- 14 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals
Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy
This study will evaluate the safety and effectiveness of a new immunosuppressive drug, sirolimus, in reducing the amount of protein in the urine in patients with membranous nephropathy.
- Trial name
- NCT00050713
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Depression
Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects
The aim of the study is to provide insight into the impact of the immunosuppressant drug sirolimus, on the antidepressant effects of the prototypal rapid-acting antidepressant medication, ketamine.
- Trial name
- NCT02487485
- Testing
- Ketamine, sirolimus
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Acute Myeloid Leukemia
A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to determine the safety and feasibility of the combination of decitabine given at a fixed dose with escalating doses of rapamycin in patients with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT00861874
- Testing
- Decitabine, Rapamycin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Rochester
Diabetes Mellitus, Type 1
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control.
- Trial name
- NCT00434850
- Testing
- Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.